Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Gastroesophageal Reflux: full-pipeline trial registry
15 of 35 indexed Gastroesophageal Reflux trials are currently recruiting.
Corpus placement: #435 of 28,707 conditions by registered trial count.
35 US clinical trials · 15 currently recruiting · #435 of 28,707 conditions by registered trial count
Gastroesophageal Reflux: 35 US clinical trials tracked, 15 recruiting.
Gastroesophageal Reflux is the subject of 35 registered US clinical trials on ClinicalTrials.gov, 15 of them currently open to new participants. 6 are in Phase 3-4 (later-stage) and 4 in Phase 1-2 (earlier-stage). The most active sponsor is Johns Hopkins University, running 3 of these trials.
Enrollment posture brief
Registry condition gastroesophageal-reflux
OPEN 15 | RECR 43% | LATE 6 | EARLY 4 | RANK #435 | SPON 3
Volume-matched condition peers
Nearest open-share peer: Acute Myelogenous Leukemia (AML) (43% recruiting · 7 trials)
Gastroesophageal Reflux lists 15 open slots (43% of 35 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Gastroesophageal Reflux on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Gastroesophageal Reflux is recruiting above its size-band peers.
15 of 35 indexed trials (42.9%) are open to enrollment, against a 39.7% average across 762 conditions with 20-99 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
Sponsorship of Gastroesophageal Reflux trials is spread across many organizations.
Johns Hopkins University accounts for 3 of 35 trials (8.6%). 30 distinct sponsors appear on at least one study for this condition label.
-
Typical Gastroesophageal Reflux enrolment sits around 85 participants.
Median target enrolment is 85 among the 34 trials that report a genuine target (sentinel values excluded). 19 of those (55.9%) plan for fewer than 100 participants.
-
Gastroesophageal Reflux research is mostly interventional.
25 interventional and 10 observational studies make up this index (71.4% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
35 total, page 1 of 1
Clinical Utility of WATS3D: A 5-Year Prospective Study
CDx Diagnostics
NCT04312633
Endoscopic Bariatric Therapies (EBTs): A Retrospective and Prospective Multicenter Registry
Weill Medical College of Cornell University
NCT04494048
Multi-Site Detection of Barrett's Esophagus in Patients Without Chronic GERD Symptoms
Case Comprehensive Cancer Center
NCT06687603
External UES Band (Shaker Pressure Band) and GERD
Medical College of Wisconsin
NCT05697393
Multi-Center Study of Panosyl-Isomaltooligosaccharides Adjunctive to PPI Therapy to Treat GERD
Microbiome Health Sciences
NCT05556824
Post-sleeve Gastrectomy Gastroesophageal Reflux Disease Prediction
Mayo Clinic
NCT04411823
Barrett's Esophagus Related Neoplasia (BERN) Project
Midwest Biomedical Research Foundation
NCT00590239
Gastrointestinal Dysmotility on Aspiration Risk
Boston Children's Hospital
NCT05455359
Transpyloric Versus Gastric Feeding in Bronchopulmonary Dysplasia
Children's Hospital of Philadelphia
NCT06534359
A Study of Breath Testing for Small Intestinal Bacterial Overgrowth
Mayo Clinic
NCT05976165
Esophageal and Gastric Registry and Biorepository
University of Louisville
NCT05180253
Efficacy Of Hiatal Closure For GERD
University of Chicago
NCT06280664
Anti-Reflux Endoscopic TX Using APC (AREA) in GERD Patients: (The AREA Study)
Midwest Veterans' Biomedical Research Foundation
NCT05570448
Establishing Pressures at the EGJ During Diaphragmatic Breathing Using High-resolution Esophageal Manometry
Mayo Clinic
NCT06329583
Compassionate Use of Domperidone for Refractory Gastroparesis
Children's Mercy Hospital Kansas City
NCT04699591
Novel Biomarkers in the Neoplastic Progression of Barrett's Esophagus
Johns Hopkins University
NCT00431756
RETHINK REFLUX Registry
Ethicon Endo-Surgery
NCT04253392
Transpyloric Feeding for Prevention of Micro-aspiration
Nemours Children's Clinic
NCT03646045
Gracie Diet for Gastroesophageal Reflux Disease
Johns Hopkins University
NCT04360252
A Study of Dexlansoprazole Modified Release Formulation to Treat Night Heartburn
Takeda
NCT00627016
ADX10059 as an add-on Therapy to Proton Pump Inhibitors (PPIs) in Patients With Gastroesophageal Reflux (GERD)
Addex Pharma S.A.
NCT00810485
Development and Validation of the Automated Evaluation of Gastrointestinal Symptoms (AEGIS) Platform
Cedars-Sinai Medical Center
NCT02436057
Effectiveness of Physiologic Testing in PPI Non-Responders
Northwestern University
NCT03202537
Tolerability Study of a Novel Microbiome Therapeutic in Subjects With Gastroesophageal Reflux Disease
ISOThrive
NCT04491734
Comparison of Laparoscopic Hill and Laparoscopic Nissen Anti-Reflux Procedures
Swedish Medical Center
NCT01260935
GERD Treatment With Transoral Incisionless Fundoplication (TIF) Following Hiatal Hernia Surgery
Peter G Mavrelis
NCT03143608
Complications, Outcomes and Revisions Following Hiatal Hernia Repair With MIROMESH
Miromatrix Medical
NCT03735862
Clinical Trial Comparing Open and Laparoscopic Nissen Fundoplication in Children
Johns Hopkins University
NCT00382850
Study Evaluating Pantoprazole Sodium Enteric-Coated Spheroid Suspension In Infants With Presumed GERD
Wyeth is now a wholly owned subsidiary of Pfizer
NCT00259012
Study Evaluating Pantoprazole in Children With Gastroesophageal Reflux Disease (GERD)
Wyeth is now a wholly owned subsidiary of Pfizer
NCT00300755
Esophageal and Laryngeal Tissue Changes in Patients Suspected of Having Laryngopharyngeal Reflux
Vanderbilt University
NCT00373997
Precision Approach to PPI Therapy in Gastroesophageal Reflux Disease
University of California, San Diego
NCT03619811
Genotype-tailored Treatment of Symptomatic Acid-Reflux in Children With Uncontrolled Asthma
Jason Lang, M.D., M.P.H.
NCT03015610
Dose-Effect of S-Tenatoprazole-Na(STU-Na) 30 mg, 60 mg, 90 mg and 120 mg in Healthy Volunteers
STEBA France
NCT00284908
Evaluation of Gastroesophageal Reflux in Patients on Continuous Positive Airway Pressure Ventilation for Obstructive Sleep Apnea
University of Pennsylvania
NCT00194376
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 2 |
| Phase 2 | 2 |
| Phase 3 | 4 |
| Phase 4 | 2 |
Top Sponsors
Named interventions
Most-linked intervention names on Gastroesophageal Reflux records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Gastroesophageal Reflux trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Gastroesophageal Reflux page
35 registered trials, 15 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 15 Gastroesophageal Reflux trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- Johns Hopkins University sponsors the most Gastroesophageal Reflux trials on record, review their full trial history before evaluating a specific study. See Johns Hopkins University's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Gastroesophageal Reflux condition card totals 35 registered trials; most-linked intervention matched placebo; top US site state Florida. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.